Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection

Hepatology

Volumn 55, Issue 4, 2012, Pages 1058-1069

  Grebely, Jason ^a   Pham, Son Truong ^b   Matthews, Gail V ^a   Petoumenos, Kathy ^a   Bull, Rowena A ^b   Yeung, Barbara ^a   Rawlinson, William ^c   Kaldor, John ^a   Lloyd, Andrew ^b   Hellard, Margaret ^d   Dore, Gregory J ^a   White, Peter A ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; REINFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOCIAL INTERACTION; SUPERINFECTION; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; SUPERINFECTION; TREATMENT OUTCOME;

EID: 84859164566     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24754     Document Type: Article

References (34)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
2. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359.
3. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-358.
4. NCHECR. HIV/AIDS Viral Hepatitis and Sexually Transmissible Infections in Australia. Annual Surveillance Report, 2008. Sydney: National Centre in HIV Epidemiology and Clinical Research; 2008.
5. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-133.
6. Grebely J, deVlaming S, Duncan F, Viljoen M, Conway B. Current approaches to HCV infection in current and former injection drug users. J Addict Dis 2008; 27: 25-35.
7. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
8. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39: 1540-1543.
9. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40(Suppl 5): S336-S338.
10. Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 2008; 93: 148-154.
11. Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 2010; 25: 1281-1284.
12. Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J Gastroenterol Hepatol 2010; 25: 1276-1280.
13. Blackard JT, Sherman KE. Hepatitis C virus coinfection and superinfection. J Infect Dis 2007; 195: 519-524.
14. Smith DM, Richman DD, Little SJ. HIV superinfection. J Infect Dis 2005; 192: 438-444.
15. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138: 123-135 e121-122.
16. Pham ST, Bull RA, Bennett JM, Rawlinson WD, Dore GJ, Lloyd AR, et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. HEPATOLOGY 2010; 52: 1564-1572.
17. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992; 87: 733-742.
18. Bukh J, Thimme R, Meunier JC, Faulk K, Spangenberg HC, Chang KM, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol 2008; 82: 8183-8195.
19. Wyatt CA, Andrus L, Brotman B, Huang F, Lee DH, Prince AM. Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol 1998; 72: 1725-1730.
20. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-1655.
21. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002; 76: 6586-6595.
22. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. HEPATOLOGY 2001; 33: 1479-1487.
23. Asselah T, Vidaud D, Doloy A, Boyer N, Martinot M, Vidaud M, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut 2003; 52: 900-902.
24. Okamoto H, Mishiro S, Tokita H, Tsuda F, Miyakawa Y, Mayumi M. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a. HEPATOLOGY 1994; 20: 1131-1136.
25. Kao JH, Chen PJ, Wang JT, Yang PM, Lai MY, Wang TH, et al. Superinfection by homotypic virus in hepatitis C virus carriers: studies on patients with post-transfusion hepatitis. J Med Virol 1996; 50: 303-308.
26. Widell A, Mansson S, Persson NH, Thysell H, Hermodsson S, Blohme I. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 1995; 60: 642-647.
27. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-88.
28. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315-324.
29. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-1483.
30. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. HEPATOLOGY 2006; 44: 1139-1145.
31. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007; 14: 413-418.
32. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. HEPATOLOGY 2008; 48: 1746-1752.
33. van de Laar TJ, Molenkamp R, van den Berg C, Schinkel J, Beld MG, Prins M, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 2009; 51: 667-674.
34. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult drug users: a prospective study of incident infection, resolution and reinfection. J Infect Dis 2009; 200: 1216-1226.